An interventional study of Personalized SCAN Targeted Epidural Modulation in Parkinson Disease, sponsored by Changping Laboratory. Recruiting at 1 site in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-19.
Sponsored by Changping Laboratory · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 279 studies in Parkinson Disease with a site in China — 128 open to participants now, 135 under way, 3 of them phase 3. Parkinson Disease · China.
Among the 279 studies in Parkinson Disease with a site in China, this one is the 204th largest by planned enrollment of the 211 interventional ones that give a count, is one of 33 that started in 2025, is one of 115 with no phase, reaches primary completion later than 55 of the 134 other live ones, and was the 204th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →128 of the 279 studies in Parkinson Disease with a site in China are open now. Recruiting first, the newest first:
The First Affiliated Hospital of Anhui Medical University · Sites in China
Ages 30–75
Hoffmann-La Roche · Sites in China, United States, Ireland and 2 more countries
Ages 40–85
Hangzhou PhecdaMed Co., Ltd. · Sites in China
Ages 18–80
Shanghai UniXell Biotechnology Co., Ltd · Sites in China
Ages 30–75
Ruijin Hospital · Sites in China
Ages 50–85
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
279 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 49 · Phase 2 28 · Phase 3 23 · Phase 4 11
First in 2003; this study’s year is marked. 33 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3 is below the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 47 across the 211 interventional studies, 215 across the 68 observational. Of the 97 that completed or were terminated, 19 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 279 have an industry lead sponsor. The 10 most frequent:
Changping Laboratory is the lead sponsor of 32 studies on the registry; 24 are open to participants now.
Changping Laboratory has 1 study filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
41 of the studies in Parkinson Disease with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07725562Phase 3Zhejiang Vimgreen Pharmaceuticals, Ltd.VG081821AC Tablets for Early to Mid-stage Parkinson's Disease | 2027-10-01 |
| NCT07028632iRegene Therapeutics Co., Ltd.The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease | 2026-12 |
| NCT07604116Synusight Biotech (Shanghai) Co., Ltd.A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA | 2026-12 |
| NCT06642454Anhui Medical UniversityA Randomized Double-Blind Active-Controlled Crossover Trial of Respiratory-Gated Versus Non-Gated Transcutaneous Auricular Vagus Nerve Stimulation for the Treatment of Motor and Non-Motor Symptoms in Parkinson's Disease | 2026-12-01 |
| NCT07384429YangPanEffects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease | 2026-12-01 |
Add all 41 to your calendar (.ics) → With an account.
Among the 279 studies in Parkinson Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if epidural modulation targeting the Somato-Cognitive Action Network (SCAN) can improve motor symptoms in adults with idiopathic Parkinson's disease (PD). It will also evaluate the safety of this treatment. The main questions it aims to answer are:
Researchers will compare participants' baseline motor function to their post-treatment results to determine if STEM is effective.
Participants will:
Background:
This is a prospective, open-label, single-center clinical trial investigating the efficacy and safety of personalized epidural modulation targeting the Somato-Cognitive Action Network (SCAN) in patients with idiopathic Parkinson's disease (PD). The study employs a two-stage intervention approach with comprehensive clinical and functional assessments. The study builds upon recent discoveries that the SCAN network shows preferential connectivity with PD-affected subcortical structures. By combining advanced neuroimaging for personalized target identification with staged therapeutic intervention, the trial aims to establish proof-of-concept for this novel neuromodulation approach. The design allows for initial non-invasive validation of target engagement through iTBS before proceeding to surgical implantation.
Study Design and Methodology:
The trial consists of two sequential stages:
- Screening and iTBS Intervention Stage (7 days) and a Washout Period (1-3 months): Eligible participants will first undergo intermittent theta-burst stimulation (iTBS) to their individualized SCAN target, identified through resting-state functional MRI and personalized-Brain-Functional-Sector (pBFS) mapping.
Participants demonstrating ≥30% improvement in motor symptoms proceed to a mandatory washout period.
Complete cessation of all neuromodulation therapies while maintaining stable PD medications.
- Surgical Intervention and Follow-up (12 months): Responsive patients undergo epidural electrode implantation over their predetermined SCAN target.
A scheduled12 months follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This experimental arm involves a comprehensive two-stage therapeutic intervention for Parkinson's disease patients: * Pre-surgical Screening Stage: * All participants first undergo non-invasive intermittent theta-burst stimulation (iTBS) targeting their individualized Somato-Cognitive Action Network (SCAN) region. * Surgical Intervention Stage (for iTBS responders): * Patients showing ≥30% improvement in motor symptoms proceed to epidural implantation of electrodes over the predetermined SCAN target.
Device: Personalized SCAN Targeted Epidural Modulation
* Stage 1: iTBS Intervention (7 days) and Washout Period (1-3 months) * All enrolled participants undergo: * Baseline clinical assessments * Structural and functional MRI with pBFS mapping * Resting motor threshold determination * Daily iTBS sessions targeting individualized SCAN coordinates: * Treatment duration: 7 consecutive days * Post-intervention evaluation at Day 7-14 * Mandatory observation window: * No neuromodulation therapies permitted * Stable PD medication regimen maintained * Monthly safety monitoring * Stage 2: Surgical Intervention and Follow-up (12 months) * Surgical Procedure: * Epidural electrode implantation * Pulse generator internalization * Epidural Modulation Stage: * Parameter optimization visits * Scheduled follow-ups at Months 1, 3, 6, 12
Change in Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III motor scores at 3 months post-stimulation(medication "off" state)
The change in Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) motor examination scores measured during the medication "off" state (after 12-hour overnight withdrawal of anti-Parkinson medications) from baseline to 3 months after initiating motor cortex stimulation. Higher scores indicate more severe motor impairment (range 0-132). A negative change indicates improvement.
Time frame: Baseline to 3 months post-stimulation
Change in MDS-UPDRS-III scores (ON/OFF states) from baseline to 12 months
Difference in Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) motor examination scores (range 0-132, higher=worse) between baseline and post-stimulation assessments during both medication ON (2 hours after levodopa dose) and OFF (after 12-hour withdrawal) states.
Time frame: Baseline, 1-week, 1/3/6/12 months post-stimulation
Change in daily OFF time duration (hours) from baseline
Reduction in self-reported daily hours of OFF periods (time when Parkinson's medications are ineffective) as recorded in patient diaries, comparing baseline to post-stimulation timepoints.
Time frame: Baseline, 1/3/6/12 months post-stimulation
Change in daily ON time duration (hours) from baseline
Increase in self-reported daily hours of good ON periods (medication effectiveness without troublesome dyskinesia) from baseline to follow-up assessments.
Time frame: Baseline, 1/3/6/12 months post-stimulation
Change in 39-item Parkinson's Disease Questionnaire summary index score from baseline
Difference in 39-item Parkinson's Disease Questionnaire (PDQ-39) total score (range 0-100, higher=worse quality of life) between baseline and follow-up assessments.
Time frame: Baseline, 1/3/6/12 months post-stimulation
Change in Clinical Global Impression (CGI) score from baseline
Improvement in clinician-rated CGI scale (range 1-7, higher=worse) assessing overall disease severity change since baseline.
Time frame: Baseline, 1/3/6/12 months post-stimulation
Change in levodopa equivalent daily dose (LEDD) from baseline
Reduction in calculated total daily dopaminergic medication dosage (mg/day) while maintaining symptom control.
Time frame: Baseline, 3/6/12 months post-stimulation
Change in Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part I (MDS-UPDRS-I) scores from baseline
Difference in MDS-UPDRS-I non-motor experiences of daily living scores (range 0-52, higher=worse) between baseline and post-stimulation assessments.
Time frame: Baseline, 1/3/6/12 months post-stimulation
Change in Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part II (MDS-UPDRS-II) scores from baseline
Difference in MDS-UPDRS-II non-motor experiences of daily living scores (range 0-52, higher=worse) between baseline and post-stimulation assessments.
Time frame: Baseline, 1/3/6/12 months post-stimulation
Change in Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part IV (MDS-UPDRS-IV) scores from baseline
Difference in MDS-UPDRS-IV motor complications scores (range 0-24, higher=worse) assessing dyskinesia and motor fluctuations.
Time frame: Baseline, 1/3/6/12 months post-stimulation
Change in Non-Motor Symptoms Scale (NMSS) score from baseline
Difference in Non-Motor Symptoms Scale total score (range 0-360, higher=worse) evaluating frequency and severity of non-motor symptoms in Parkinson's disease.
Time frame: Baseline, 1/3/6/12 months post-stimulation
Change in Pittsburgh Sleep Quality Index (PSQI) score from baseline
Difference in Pittsburgh Sleep Quality Index global score (range 0-21, higher=worse sleep quality) assessing sleep disturbances and patterns.
Time frame: Baseline, 1/3/6/12 months post-stimulation
Change in Hamilton Depression Rating Scale-17 (HAMD-17) score from baseline
Difference in 17-item Hamilton Depression Rating Scale scores (range 0-52, higher=more severe depression) evaluating depressive symptoms.
Time frame: Baseline, 1/3/6/12 months post-stimulation
Change in Hamilton Anxiety Rating Scale (HAMA) score from baseline
Difference in Hamilton Anxiety Rating Scale scores (range 0-56, higher=more severe anxiety) assessing anxiety symptoms.
Time frame: Baseline, 1/3/6/12 months post-stimulation
Change in Mini-Mental State Examination (MMSE) score from baseline
Difference in Mini-Mental State Examination total score (range 0-30, higher=better cognitive function) assessing global cognitive status.
Time frame: Baseline, 3/12 months post-stimulation
Change in Montreal Cognitive Assessment (MoCA) score from baseline
Difference in Montreal Cognitive Assessment total score (range 0-30, higher=better cognitive function) evaluating multiple cognitive domains.
Time frame: Baseline, 3/12 months post-stimulation
Started Dec 2025 (actual). Primary completion is estimated for Sep 2026, 9 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 9 months is below that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Changping Laboratory